Cargando…

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL

Recently, chimeric antigen receptor (CAR)-T cell therapy has shown great promise in treating haematological malignancies(1–7). However, CAR-T cell therapy currently has several limitations(8–12). Here we successfully developed a two-in-one approach to generate non-viral, gene-specific targeted CAR-T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jiqin, Hu, Yongxian, Yang, Jiaxuan, Li, Wei, Zhang, Mingming, Wang, Qingcan, Zhang, Linjie, Wei, Guoqing, Tian, Yue, Zhao, Kui, Chen, Ang, Tan, Binghe, Cui, Jiazhen, Li, Deqi, Li, Yi, Qi, Yalei, Wang, Dongrui, Wu, Yuxuan, Li, Dali, Du, Bing, Liu, Mingyao, Huang, He
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452296/ https://www.ncbi.nlm.nih.gov/pubmed/36045296 http://dx.doi.org/10.1038/s41586-022-05140-y

Ejemplares similares

Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study
por: Hu, Yongxian, et al.
Publicado: (2023)

Intelligent tunable CAR-T cell therapy leads the new trend
por: Cheng, Jiayi, et al.
Publicado: (2023)

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
por: Zurko, Joanna, et al.
Publicado: (2022)

Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
por: Itzhaki, Orit, et al.
Publicado: (2020)

HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma
por: Xu, Xueer, et al.
Publicado: (2023)

Biomarkers in NHL
por: Malek, Sami N.
Publicado: (2011)

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy
por: Zhang, Mingming, et al.
Publicado: (2021)

PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL
por: Rui, Liu, et al.
Publicado: (2023)

Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
por: Song, Fengmei, et al.
Publicado: (2023)

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
por: Gauthier, Jordan, et al.
Publicado: (2022)

Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL
por: Korell, Felix, et al.
Publicado: (2020)

Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
por: Bezerra, Evandro D., et al.
Publicado: (2022)

Stem cell hunt in NHL
por: Merkel, Olaf, et al.
Publicado: (2015)

NHL - Extranodal T-cell lymphoma
por: Devi, Seema, et al.
Publicado: (2015)

Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Anti‐Leukemia Efficacy of CAR‐T Cells via SOCE‐Calcineurin‐NFAT and Glycolysis Pathways
por: Shao, Mi, et al.
Publicado: (2022)

Exploring Potential Germline-Associated Roles of the TRIM-NHL Protein NHL-2 Through RNAi Screening
por: Davis, Gregory M., et al.
Publicado: (2017)

TRIM-NHL protein, NHL-2, modulates cell fate choices in the C. elegans germ line
por: Brenner, John L., et al.
Publicado: (2022)

Comparative structural analyses of the NHL domains from the human E3 ligase TRIM–NHL family
por: Chaikuad, Apirat, et al.
Publicado: (2022)

Non-Hodgkin Lymphoma (NHL) in Pakistan
por: Pervez, Shahid
Publicado: (2012)

Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement
por: Zhang, Qiqi, et al.
Publicado: (2022)

The TRIM-NHL protein NHL-2 is a co-factor in the nuclear and somatic RNAi pathways in C. elegans
por: Davis, Gregory M, et al.
Publicado: (2018)

Modeling interaction of Glioma cells and CAR T-cells considering multiple CAR T-cells bindings
por: Li, Runpeng, et al.
Publicado: (2023)

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies
por: Hu, Yongxian, et al.
Publicado: (2022)

Cytokine Release Syndrome Is an Independent Risk Factor Associated With Platelet Transfusion Refractoriness After CAR-T Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
por: Liu, Yadan, et al.
Publicado: (2021)

Intraoperative navigation system with a multi-modality fusion of 3D virtual model and laparoscopic real-time images in laparoscopic pancreatic surgery: a preclinical study
por: Du, Chengxu, et al.
Publicado: (2022)

Evaluating and Diagnosing Road Intersection Operation Performance Using Floating Car Data
por: Chen, Deqi, et al.
Publicado: (2019)

CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges
por: Hu, Yongxian, et al.
Publicado: (2020)

Born at the Wrong Time: Selection Bias in the NHL Draft
por: Deaner, Robert O., et al.
Publicado: (2013)

S271: AN UPDATED FOLLOW-UP OF BRL-101, CRISPR-CAS9-MEDIATED GENE EDITING OF THE BCL11A ENHANCER FOR TRANSFUSION-DEPENDENT BETA-THALASSE
por: Fu, Bin, et al.
Publicado: (2023)

Clinical characteristics and outcomes of newly diagnosed patients with HIV‐associated aggressive B‐cell NHL in China
por: Wang, Chaoyu, et al.
Publicado: (2022)

Cloning of the Soybean GmNHL1 Gene and Functional Analysis under Salt Stress
por: Liu, Lu, et al.
Publicado: (2023)

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
por: Rejeski, Kai, et al.
Publicado: (2023)

Immunotherapy for T-Cell ALL and T-NHL: Highlights From SOHO 2020
Publicado: (2021)

PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise
por: Bou Zeid, Naji, et al.
Publicado: (2023)

Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy
por: Ding, Shuyi, et al.
Publicado: (2023)

Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission
por: Wang, Yiyun, et al.
Publicado: (2021)

B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS
por: Wang, Sophia S., et al.
Publicado: (2022)

Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
por: Zhu, Feng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0bpcqa1ovkqfntbqj56opaua22